Cooley advised Kezar Life Sciences Inc. on its $86.3 million initial public offering of 5,750,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Cooley partners Laura Berezin and Rob Phillips led the team advising Kezar.
Jefferies and Cowen and Company acted as joint book-running managers for the offering. Wells Fargo and William Blair also acted as book-runners.
Kezar is a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. It now trades on the Nasdaq Global Select Market under the symbol “KZR.”